Roundview Capital LLC Has $11.37 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Roundview Capital LLC lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 68,568 shares of the company's stock after selling 2,117 shares during the quarter. Johnson & Johnson makes up approximately 0.8% of Roundview Capital LLC's portfolio, making the stock its 25th biggest position. Roundview Capital LLC's holdings in Johnson & Johnson were worth $11,371,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC grew its holdings in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the period. Segall Bryant & Hamill LLC grew its holdings in Johnson & Johnson by 1.0% during the fourth quarter. Segall Bryant & Hamill LLC now owns 36,670 shares of the company's stock worth $5,303,000 after acquiring an additional 367 shares during the period. Modern Wealth Management LLC grew its holdings in Johnson & Johnson by 35.6% during the fourth quarter. Modern Wealth Management LLC now owns 33,386 shares of the company's stock worth $5,149,000 after acquiring an additional 8,769 shares during the period. Finally, Prospect Financial Group LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $409,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. UBS Group increased their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Bank of America increased their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $1.27 during midday trading on Friday, reaching $168.29. 6,199,690 shares of the company traded hands, compared to its average volume of 8,375,731. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a fifty day moving average price of $156.08 and a 200 day moving average price of $155.78. The firm has a market capitalization of $404.92 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm posted $2.82 EPS. The firm's quarterly revenue was up 5.8% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.